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Abstract
Background: Naltrexone is an opioid antagonist used in many different conditions, both licensed and unlicensed. It
is used at widely varying doses from 3 to 250 mg. The aim of this review was to extensively evaluate the safety of
oral naltrexone by examining the risk of serious adverse events and adverse events in randomised controlled trials
of naltrexone compared to placebo.
Methods: A systematic search of the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, other
databases and clinical trials registries was undertaken up to May 2018. Parallel placebo-controlled randomised
controlled trials longer than 4 weeks published after 1 January 2001 of oral naltrexone at any dose were selected.
Any condition or age group was included, excluding only studies in opioid or ex-opioid users owing to possible
opioid/opioid antagonist interactions. The systematic review used the guidance of the Cochrane Handbook and
Preferred Reporting Items for Systematic Reviews and Meta-analyses harms checklist throughout. Numerical data
were independently extracted by two people and cross-checked. Risk of bias was assessed with the Cochrane risk-
of-bias tool. Meta-analyses were performed in R using random effects models throughout.
Results: Eighty-nine randomised controlled trials with 11,194 participants were found, studying alcohol use disorders
(n = 38), various psychiatric disorders (n = 13), impulse control disorders (n = 9), other addictions including
smoking (n = 18), obesity or eating disorders (n = 6), Crohn’s disease (n = 2), fibromyalgia (n = 1) and cancers (n = 2).
Twenty-six studies (4,960 participants) recorded serious adverse events occurring by arm of study. There was no
evidence of increased risk of serious adverse events for naltrexone compared to placebo (risk ratio 0.84, 95%
confidence interval 0.66–1.06). Sensitivity analyses pooling risk differences supported this conclusion (risk difference −0.
01, 95% confidence interval −0.02–0.00) and subgroup analyses showed that results were consistent across different
doses and disease groups. Secondary analysis revealed only six marginally significant adverse events for naltrexone
compared to placebo, which were of mild severity.
Conclusions: Naltrexone does not appear to increase the risk of serious adverse events over placebo. These findings
confirm the safety of oral naltrexone when used in licensed indications and encourage investments to undertake efficacy
studies in unlicensed indications.
Trial registration: PROSPERO 2017 CRD42017054421.
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Background
Naltrexone is a pure opioid antagonist with activity at multiple
opioid and non-opioid human receptors. Its licensed uses are
as an aid to prevent relapse in alcohol use disorders (AUDs)
and opioid addiction after withdrawal, and in the combination
tablet naltrexone–bupropion for obesity [1]. These conditions
are all major global health problems, with rising rates of dis-
ability and death occurring in many countries [2, 3]. Despite
concern about the impact of these diseases and the need for
treatment, naltrexone is currently under-utilised across most
countries, particularly for AUDs [4–6].
At normal or higher doses (≥50 mg), naltrexone is also
used off-label for several addictions and impulse control
disorders that currently have no licensed drug treat-
ments, such as amphetamine and cocaine addiction [7,
8], impulse control disorders [9–11], eating disorders
[12] and autism spectrum disorders [13].
Following experimental findings that low doses of nal-
trexone result in tumour growth suppression [14] and im-
mune modulation [15], it is increasingly used at doses of
around 4.5 mg. This is known as low dose naltrexone
(LDN). Small-scale clinical trials of LDN have been con-
ducted in, for example, Crohn’s disease, multiple sclerosis,
fibromyalgia and HIV infection, where the evidence has
shown efficacy and/or low toxicity [16–19]. Other condi-
tions for which LDN is used, such as chronic fatigue syn-
drome (also known as myalgic encephalomyelitis), complex
regional pain syndrome and auto-immune disorders, are
still awaiting randomised clinical trials (RCTs) [20–22].
LDN is now licensed as an adjunct in HIV infection for
over-the-counter sales in Kenya and Nigeria [23]. In
Norway, it has been associated with a reduction in prescrip-
tions for more conventional treatments in some conditions
[24, 25]. In the UK, around 1,400 NHS prescriptions for
LDN are issued per year ([26]; personal communication
from D. Steinke, October 2016: LDN usage in CPRD), while
over 12,000 people have received a private prescription in
the last 10 years (personal communication from S. Dickson,
October 2017: LDN private prescriptions dispensed from
Dicksons Chemist Glasgow in past 10 years).
Known safety issues for naltrexone
Naltrexone is contra-indicated in those currently using
opioids due to the possibility of serious adverse events
(SAEs) of either over-rapid opioid withdrawal or over-
dose of opioids, which can be life-threatening [1, 27].
These SAEs are of a different nature from those occur-
ring in non-opioid users.
Concerns about naltrexone causing liver toxicity origi-
nated from several high-dose studies (up to 300 mg) in
the 1980s [28]. Because of these results, the US Food
and Drug Administration (FDA) initially required a
“black-box warning” about hepatotoxicity in the package
insert for naltrexone; the FDA specifies such warnings to
call attention to serious or life-threatening risks. How-
ever, because there are no known cases of hepatic failure
due to naltrexone [29, 30], the warning was eventually
removed in 2013 [27]. The British National Formulary
cautions avoidance in cases with acute hepatitis, hepatic
failure or severe impairment, and in severe renal impair-
ment. Known side effects include nausea, vomiting, ab-
dominal pain, decreased appetite, dizziness, lethargy,
headaches and sleep disorders [1, 29].
Drug safety in clinical trials
The quality of recording and reporting of harms in clin-
ical trials has historically been less rigorous than that of
efficacy [31, 32]. Progress has been aided by the intro-
duction of standard definitions for adverse events (Box
1); the requirement to keep detailed records of adverse
events (AEs) in clinical trials, introduced in 2001; the
International Committee of Medical Journal Editors’
endorsement of the reporting standards suggested in
the Consolidated Standards of Reporting Trials (CON-
SORT) extension for harms published in 2004 [33], and
the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) harms checklist pub-
lished in 2016 [34]; and the requirement to record out-
comes, including AEs and SAEs, for RCTs registered on
clinical trials registries since 2014 in the European
Union (EU) [35] and 2017 in the USA [36]. An evi-
dence synthesis of harms (SAEs and AEs) would help
to yield a more accurate safety profile of naltrexone.
Why is it important to do this review?
There have been several descriptive, non-systematic safety re-
views of naltrexone recently [37, 38], but none to date have
concentrated on AEs and SAEs in clinical trials of naltrexone.
Including studies from a wide range of conditions and con-
centrating only on a specific adverse outcome that has a regu-
latory definition should enable a large quantity of high-quality
harms data to be collected. People with addictions are reluc-
tant to take, and therapists to prescribe, one drug to over-
come addiction to another drug, including alcohol [39, 40],
and practitioners remain concerned about the risk for liver
toxicity with naltrexone [41–43]. Hence, evidence about the
safety of naltrexone is needed. Patients taking naltrexone and
LDN may do so for prolonged periods of time; therefore, es-
tablishing the longer-term safety of naltrexone is particularly
important. It may only be possible to discover increased or
decreased rates of some SAEs, particularly cardiovascular or
cerebrovascular events or cancers in meta-analyses, owing to
their generally low background rates [44].
The primary aim of this review was to examine SAEs oc-
curring in clinical trials of oral naltrexone, given for any con-
dition apart from opioid or ex-opioid use, compared to
placebo. Our focus on SAEs accords with the recent em-
phasis on understanding and preventing enduring or
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permanent patient harm (rather than examining every AE),
as highlighted, for example, in the Dalton review of duty of
candour [45]. Further aims were to investigate possible con-
founders of risk of SAEs for naltrexone by subgroup analyses
of disease group, dosage and length of study; to examine spe-
cific SAEs (deaths, cardiovascular or cerebrovascular events
and cancers); and to examine withdrawals and withdrawals
due to AEs in the same clinical trials. A secondary aim was
to examine AEs for naltrexone compared to placebo.
Methods
The review followed the Cochrane Handbook for guidance
throughout [46] and the PRISMA harms extension [34]. The
protocol was registered on the PROSPERO website in
January 2017, registration number CRD42017054421. This
can be accessed at https://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42017054421.
Selection criteria
Any parallel-designed RCT longer than 4 weeks, in partic-
ipants of any age and for any condition, in which oral nal-
trexone was compared to placebo was included. Studies in
which opioid or ex-opioid use was specified in the
protocol were excluded owing to the possibility of opioid/
opioid antagonist interactions occurring. Only studies
published after 1 January 2001 were included, owing to
the widespread introduction of regulations requiring the
recording of AEs and reporting of SAEs in RCTs from that
year [47].
Outcomes
The primary outcome measure was the number of par-
ticipants with an SAE recorded in the naltrexone arm
compared to the placebo arm. The investigator’s judge-
ment as to whether an SAE had occurred and any caus-
ality was followed, as suggested by the International
Conference on Harmonisation (ICH) (Box 1). Where
no definition was given, the definition(s) from the de-
tailed guidance CT-3 for the EU [48] and by the FDA
for the USA [49] as summarised in Box 1 was used to
support our judgement. The secondary outcome was
the type of AEs reported in either treatment arm.
Search methods for identifying studies
The following electronic databases were searched:
Cochrane Central Register of Controlled Trials
Box 1 Definitions of harms connected to the use of drugs in clinical trials
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) [50] developed
definitions for use in clinical trials which were then incorporated into EU [48] and US [49] law. The ICH (1994) gave the following definitions:
AE: Adverse event. An AE is defined as “Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal
product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any
unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated
with the use of a medicinal product, whether or not considered related to the medicinal product”.
SAE: Serious adverse event. An SAE is defined as “Any untoward medical occurrence or effect that at any dose results in death, is life-
threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity,
or is a congenital anomaly or birth defect”.
These characteristics/consequences have to be considered at the time of the event. For example, regarding a life-threatening event, this
refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically
might have caused death if it were more severe.
Some medical events may jeopardise the subject or may require an intervention to prevent one of the above characteristics/
consequences. Such events (hereinafter referred to as ‘important medical events’) should also be considered as ‘serious’ in accordance
with the definition. (US regulations state “…and may require…” [49] rather than “…or may require…”).
The regulations state that “the judgement as to whether the event is serious is usually made by the reporting investigator” [48] and that
“the assessment of whether there is a reasonable possibility of a causal relationship is usually made by the investigator” [48]. In this
systematic review all judgements on seriousness and causality by study authors were therefore accepted.
The ICH differentiates seriousness, as defined above, from severity, which relates to the intensity of an event. AEs may be severe but
relatively minor, for example, a severe headache. Regulations, and this systematic review, are only concerned with serious events.
ADR: Adverse drug reaction. All noxious and unintended responses to a medicinal product related to any dose.
Side effect: Negative (unfavourable) or positive (favourable) effects of a drug.
In randomised controlled trials, such definitions are best avoided as they require an assessment of causal link between an AE and the
drug and hence could result in biased data collection [33].
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(CENTRAL), PubMed MEDLINE, EMBASE (via
OVID), Web of Science Core Collection, PsycINFO (via
OVID) and International Pharmaceutical Abstracts via
OVID (Additional file 1). There were no language re-
strictions. No terms for AE or side effects were in-
cluded to avoid over-restrictive selection of studies with
the potential risk of outcome reporting bias [51–53].
The final date of searches was May 2018.
Further sources were relevant systematic reviews con-
taining clinical trials of naltrexone, and journal articles
being assessed for inclusion in this review. The World
Health Organization International Clinical Trials Regis-
try, the US clinical trials registry, clinicaltrials.gov and
the European Union Clinical Trials Registry EudraCT
were searched using the word “naltrexone”. These are
good sources of unpublished but completed clinical tri-
als [36]. Where a study appeared unpublished, the lead
investigator was contacted to confirm this was so. On-
going studies were recorded, to enable future updating
of this systematic review. Grey literature was included
in the review from clinical trial registries, conference
abstracts listed within CENTRAL, regulatory submis-
sions to the US FDA for drug licences and unpublished
studies located from previous systematic reviews.
Data collection and management
All screening and data extraction were undertaken by
two researchers independently (MB and SB for screen-
ing and MB and AM for data extraction), and results
were compared to draw up a final list. Any differences
were resolved by discussion, with occasional input from
a third reviewer (HvM, MP, SR or LR). Initial screening
eliminated studies using the title and abstract, with full
papers examined to select the final included studies. All
searches were downloaded to Endnote referencing soft-
ware, where duplicates of papers were removed, and
multiple papers linked to the same study identified.
The numbers found at each stage and reasons for deci-
sions were recorded.
Data were recorded on data extraction forms. Quantita-
tive data for the primary and secondary outcomes, enrol-
ment numbers and withdrawals (numbers and reasons),
SAEs (both number of participants with an SAE and total
number of SAEs, and descriptions) and AEs (total num-
bers per Medical Dictionary for Regulatory Activities
(MedDRA) preferred term) were extracted onto an Excel
spreadsheet. Website appendices, subsidiary studies and
any published protocols were examined for relevant infor-
mation. Results on clinicaltrials.gov and on EudraCT were
cross-checked with the data available in the study report.
Quality assessment
The Cochrane risk-of-bias tool [54] was adapted for the
outcome measures in this review, highlighting eight
areas of trial conduct and reporting. The CONSORT
extension for harms [33] was used to inform the choice
of criteria. The areas chosen were:
 Random sequence generation (selection bias)
 Allocation concealment (selection bias)
 Blinding of participants and personnel to
randomisation (performance bias)
 Blinding of outcome assessment (detection bias)
 Adequate outcome data reporting (attrition bias)
 Adequate collection of AEs and SAEs (attrition bias)
 Adequate reporting of SAEs (reporting bias)
 Other bias (e.g. commercial sponsorship, placebo
run-in periods)
A risk of bias table was drawn up which included the
comments drawn directly from the papers, followed by a
judgement for each study. Judgements were made by MB
and all decisions reviewed by SR, with occasional discus-
sions with a third reviewer in order to reach consensus.
The results were used to identify studies at low risk of bias
in all eight categories (low risk studies), the remaining
studies having at least one category judged not low risk.
Measures of treatment effect
A corresponding meta-analysis was performed using
data extracted from journal publications and other
sources (clinicaltrials.gov and data supplied by authors)
wherever relevant. The pooled risk ratio (RR) was com-
pared across trials reporting SAEs in the naltrexone
arm compared to the placebo arm for events recorded
during active treatment (naltrexone or placebo). Be-
cause participants may have multiple identical SAEs in
one clinical trial, or more than one SAE which could be
related, the RR was analysed per participant rather than
per event. A sensitivity analysis of risk difference (RD)
was performed because it uses data from all studies
including those with no events in either arm. Meta-ana-
lyses for the RR of individual MedDRA preferred-term
AEs, withdrawals, withdrawals due to AEs and deaths
were also performed. Associated 95% confidence inter-
vals were recorded throughout.
Data synthesis and assessment of heterogeneity
Although there was clinical heterogeneity among stud-
ies, meta-analysis was appropriate because the com-
parator and outcome measure was the same for all
studies and the direction of effect was likely to be
similar [55]. The programme R was used for all
meta-analyses (R Foundation for Statistical Comput-
ing, Vienna, Austria). Studies with events in one arm
only were included by applying the continuity correc-
tion of adding 0.5 to all cells of a 2 × 2 table of results
for each study [56, 57]. Double zero studies (i.e.
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studies that report zero events in each treatment arm)
were excluded from the analysis, as recommended in
the Cochrane Handbook. Data were analysed on an
intention-to-treat basis. Clinical heterogeneity was ac-
knowledged by using random effects models in all
analyses. Statistical heterogeneity was examined with
the I2 statistic. Values of less than 25% represent low
heterogeneity, and above 75% represent high hetero-
geneity [55]. A univariate and multivariate meta-re-
gression was used to explore further causes of
heterogeneity involving covariates, including age, gen-
der, year of publication, length of trial and quality of
study (i.e. low or high risk of bias).
Studies with multiple treatment groups
Studies trialling multiple drugs or therapies (e.g. drug plus
naltrexone compared to drug, or a four-arm factorial de-
sign) were included when there was a suitable placebo
arm for comparison with naltrexone. Studies with a fixed
combination of naltrexone and another drug in which the
comparator was a single placebo were not included. This
excluded the combination tablet of slow-release naltrex-
one–bupropion. In studies with multiple naltrexone arms
and only one placebo arm (e.g. if different dosages of nal-
trexone were trialled), data from the placebo arm were di-
vided to match the naltrexone arms by the proportions of
participants recruited to each naltrexone arm. This
avoided any double counting of the placebo arm. In trials
with multiple psychotherapeutic interventions in different
arms, the results of these could be combined, as long as
the same interventions were in the placebo arms.
Missing data
If data were missing or ambiguous (e.g. if it was not
clear from a paper if SAEs occurred or if there were
discrepancies in data between the paper and the web-
site clinicaltrials.gov), lead authors were contacted for
further information. Records were kept of all such cor-
respondence, including where this resulted in changes
to the data. In studies lacking specific comments on
SAEs, judgement was sometimes necessary to deter-
mine the presence or absence of SAEs, depending on
the extent of information provided about AEs. Reasons
for decisions were recorded, quoting the relevant text
or table from the study. All studies involving judge-
ments on data were judged unclear for risk of reporting
bias.
Subgroup and sensitivity analyses
Subgroup analyses of disease or condition and dose
were defined a priori with a rationale for why such dif-
ferences in rates of SAEs may exist [55]. Additionally,
length of study was added as a post hoc analysis owing
to its potential modifying effect on rates of SAEs. Sensi-
tivity analyses including only studies at low risk of bias
in all categories explored the robustness of findings to
risks of bias [55]. Other sensitivity analyses were ex-
plored following results of data analysis to test the ro-
bustness of the findings.
Assessment of reporting biases
This review attempted to reduce publication bias by using
wide-ranging search strategies, by including publications
that were not in English, and by looking for unreported
clinical trials on clinical trials registries. Reporting bias
was assessed visually for each meta-analysis using funnel
plots and the relevant statistical analyses.
Results
Trial flow: flow diagram and numbers
The electronic searches identified 7873 citations, and a
further 995 records identified from clinical trials web-
sites (821), systematic reviews (157) and references in
other papers (17). Deleting duplicate references reduced
this to 4738 records, of which 4390 were excluded on
the basis of examining the abstracts. Full-text articles
were obtained for 348 citations. From these, 96 cita-
tions were excluded and 163 were subsidiary papers.
Thus, 89 primary studies were identified (Additional
file 2). The numbers identified at each stage through
from initial searching to quantitative analyses, and the
reasons for excluding studies, are given in a PRISMA
2009 flow diagram (Fig. 1) [58].
Characteristics of included studies
Eighty-nine studies (11,194 participants) were found
that fulfilled the review criteria, including publication
after 1 January 2001. Three studies were excluded be-
cause they only gave total participant numbers, leav-
ing 86 studies (10,957 participants) from which data
could potentially be extracted for analysis. Table 1
summarises the characteristics of included studies by
broad categories, while Additional file 3: Table S1
provides the details of each study. The target dose of
naltrexone varied from 3 mg to 250 mg. The most
frequent conditions were AUDs (36 studies). In a fur-
ther 21 studies, including studies of HIV infection,
psychiatric disorders, addictions and smoking, partic-
ipants had a dual diagnosis including AUDs. Other
studies were of various psychiatric disorders, impulse
control disorders, other addictions, obesity, Crohn’s
disease, fibromyalgia and cancers. The patient groups
in many of the studies tended to have complex
problems, multi-morbidity, present or past multiple
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addictions or illnesses and to be taking multiple
drugs as well as the trial drugs.
Results of the quality assessment
The results of the Cochrane risk of bias assessments
for all studies are summarised in Additional file 4:
Table S2. Twelve studies were judged to have a low
risk of bias in all eight categories. These studies en-
rolled a total of 2,540 participants (28%). Eighteen
studies (20%) were low risk for six or seven of the
categories, and 14 studies (16%) were low risk in two
or fewer categories.
Prevalence and nature of serious adverse events
In events ascribed to a particular study arm, naltrex-
one or placebo, a total of 315 SAEs were recorded
among 260 participants. The number of participants
having at least one SAE was 119 in the naltrexone
arms and 141 in the placebo arms. Among the 315
SAEs, nine deaths were reported, three in the naltrex-
one arms and six in the placebo arms. Although
examining the nature and causality of SAEs was
beyond the scope of this study, wherever such data
were provided, they were extracted. Our descriptive
review of these limited data suggested that there were
no differences between the two treatment arms in
terms of the nature of SAEs. Among the included
studies, AEs were reported across 20 independent
comparisons. A total of 7,017 AEs (involving 188
MedDRA preferred-term events) were identified:
3,938 in the naltrexone arm and 3,079 in the placebo
arm (Additional file 5: Table S3). All AEs were re-
ported as being mild-moderate in nature.
Statistical tests and results
Serious adverse events
There was no evidence of any difference between nal-
trexone and placebo in the meta-analysis of RR of
SAEs. A total of 31 comparisons from the 26 studies
recording the number of SAEs by study arm were ana-
lysed. The pooled RR for the number of participants
experiencing at least one SAE for naltrexone compared
to placebo was not statistically significant (RR 0.84, 95%
CI 0.66–1.06). Tests for heterogeneity showed low
Fig 1 PRISMA 2009 flow diagram. WHO World Health Organization; EudraCT European Clinical Trials Database
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statistical heterogeneity (I2 = 0%). The forest plot for this
result is shown in Fig. 2. The pooled RD for the number
of participants experiencing at least one SAE for naltrex-
one compared to placebo was non-significant (RD −0.01,
95% CI −0.02–0.00). Heterogeneity was low (I2 = 7%). The
forest plot for RR of death showed no increased risk of
death for naltrexone over placebo (RR 0.79, 95% CI 0.33–
1.91). Although specified in the protocol, no meta-analysis
of the specific SAEs due to cardiovascular or cerebrovas-
cular events or cancers was undertaken owing to the low
number of events recorded. Univariate and multivariate
meta-regression analysis did not reveal any significance
for any of the covariates.
Adverse events
A secondary analysis of 188 AEs (Additional file 5:
Table S3) revealed only six statistically significant
MedDRA preferred-term AEs. These were decreased
appetite (RR 1.44, 95% CI 1.09–1.91), dizziness (RR
1.45, 95% CI 1.15–1.83), nausea (RR 1.59, 95% CI
1.37–1.84), sleepiness (RR 1.45, 95% CI 1.07–1.97),
sweating (RR 1.89, 95% CI 1.25–2.87) and vomiting
(RR 1.91, 95% CI 1.51–2.42). However, sensitivity ana-
lysis revealed these to be of only mild nature and com-
mon among all patients.
Withdrawals and withdrawals due to AEs
There was no evidence of a difference between nal-
trexone and placebo in the meta-analysis of RR of
withdrawals (RR 0.99, 95% CI 0.93–1.05, I2 = 8%),
whereas there was an increased risk of withdrawal
due to AEs (RR 1.33, 95% CI 1.06–1.67, I2 = 0%).
Subgroup and sensitivity analyses
In pre-specified subgroup analyses of RR of SAEs, there
was no difference in results for different doses (Fig. 3)
of naltrexone or for different disease groups/conditions.
Because of the limited number of studies with dosages
<26 mg compared to the other dosage groups, we spe-
cify that these results should be interpreted with cau-
tion. The assessment of SAEs by disease group is
shown in Additional file 6: Figure S1. This analysis did
not display any statistical significance. A post hoc ana-
lysis by length of study showed no difference in risk be-
tween studies of ≤15 weeks duration (RR 0.74, 95% CI
0.53–1.02, I2 = 0%) compared to studies >15 weeks dur-
ation (RR 0.96, 95% CI 0.69–1.34, I2 = 0%). Sensitivity
analysis of the low risk of bias studies (RR 0.97, 95% CI
0.61–1.54, I2 = 0%) showed no difference in risk com-
pared with studies at higher risk of bias (RR 0.80, 95% CI
0.61–1.05, I2 = 0%) (Additional file 7: Figure S2).
Assessment for publication bias
There was no evidence of funnel plot asymmetry to in-
dicate publication bias for the RR of SAEs or for the RR
of withdrawals or withdrawals due to AEs. The funnel
plot for the main analysis is included as Fig. 4.
Discussion
Summary of main findings
This meta-analysis of 89 RCTs based on 11,194 partici-
pants showed no evidence of an increased risk of SAEs
occurring for naltrexone compared to placebo. These
findings were consistent across trials with varying dur-
ation, dosages and index conditions, suggesting that
naltrexone is safe to use across a wide variety of li-
censed and non-licensed indications. We found that
AEs such as dizziness, nausea and vomiting are poten-
tially more common for naltrexone compared to pla-
cebo. However, this finding should be interpreted with
Table 1 Summary of characteristics of included studies
Category Characteristics of participants
in study
Number
of studies
Disease or condition AUD 38
Drug addiction or
smoking ± AUD
18
Psychiatric disorders ± AUD 13
Impulse control disorders 9
Obesity or eating disorders 6
Inflammatory disorders 3
malignancies 2
Target dose of
naltrexonea (mg)
≤4.5 5
16–49 7
50 61
100 12
>100 8
Mean age where
givenb (years)
10 to <20 2
20 to <30 2
30 to <40 11
40 to <50 62
50 to <60 3
≥60 2
Length of studyc (weeks) 4–7 5
8–11 17
12–15 42
16–25 18
26–52 6
AUD alcohol use disorder
a3 studies were multi-arm dose-finding studies
b82 studies
c88 studies
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caution because data reporting for AEs was poor (fewer
than 21 studies contributed to the AE analyses).
Strengths and limitations
There were several strengths of this review. One was
the size, which was sufficiently large in both number of
participants and number of studies that it would have
enabled the detection of specific harms due to a drug.
Papanikolaou and Ioannidis [59] calculated the sample
size of a systematic review needed to detect a rare event
(0.25%) occurring in about 1% of subjects as 4000 sub-
jects (80% power and α = 0.05), and this systematic re-
view contained over 10,000 subjects from 89 studies. In
addition, this review included a broad range of studies
from different countries, settings and disease groups,
including patients with multiple morbidities or
addictions. These latter complex scenarios more closely
reflect clinical practice than the usual restrictive entry
criteria of clinical trials. Hence, the relative effect size
found is likely to be generalisable [60]. Our method-
ology for examining the outcome measures which were
not the primary outcome measures in any of the clin-
ical trials but are now part of the standard reporting of
clinical trials reduced the risk of reporting and publica-
tion bias [61], as did the use of clinical trials registries.
It is likely that some studies inadequately reported
and/or recorded SAEs. Therefore we checked and re-
corded any instances of discrepancies in data similar to
previous reports [62]. We consider it unlikely that the
missing or mis-recorded SAEs would have changed the
conclusions of the meta-analysis, because there were no
systematic differences between those studies adequately
and inadequately reporting SAEs, and because the
Fig 2 Forest plot of risk ratio (RR) of serious adverse events in RCTs of naltrexone vs placebo. Data in parentheses show the mean or range of
participants’ age and the percentage of male or female participants. Double zero studies (i.e. those which reported zero events in each treatment
group) were excluded from the meta-analysis. This also applies for all the subgroup analyses (for dose, disease and time)
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sensitivity analyses, particularly that including only
studies with an overall low risk of bias, supported the
main conclusion. There could have been
under-recording of SAEs in studies with high attrition
rates if follow-up was poor. Additionally, because ad-
herence to the CONSORT extension for harms rec-
ommendations [33] was poor in many studies,
particularly in the use of standardised definitions and
Fig 3 Forest plot of the subgroup analysis by dose of the risk ratio (RR) of serious adverse events in RCTs of naltrexone vs placebo. Data in
parentheses show the mean or range of participants’ age and the percentage of male or female participants. Double zero studies (i.e.
those which reported zero events in each treatment group) were excluded from the meta-analysis
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the descriptions of events, we were unable to under-
take any qualitative analysis of results.
This review was limited to studies of oral naltrexone,
excluding studies involving current or prior opioid ad-
diction or use. Our assessment of SAEs by disease
group should only be considered as exploratory because
classifying the populations into specific disease groups
was not clear-cut owing to the predominance of AUDs
even in studies of other disorders.
While the primary aim of this study was to examine
SAE data from RCTs, we did examine AEs in a secondary
analysis, but this analysis was based on limited data identi-
fied in the journal publication and the registry report. Pre-
vious evidence has also shown that the assessment and
reporting of AEs is often inconsistent and incomplete
across the studies. For example, a large safety review of 44
studies [63] of naltrexone for AUDs found that AEs were
often not collected using standardised measures, that the
methods for systematically capturing AEs were often not
reported, and the reporting of AEs was highly selective.
Recording of AEs can be hampered by the presence of
nocebo (harmful) effects (i.e. worsening symptoms dur-
ing placebo treatment), which can vary disease by dis-
ease. Particularly in alcohol and drug addiction, placebo
and nocebo mechanisms could impact on the thera-
peutic outcomes and side effects of treatments [64]. Al-
though less likely in the recording of SAEs owing to
their seriousness [64], this may have also impacted our
results.
Finally, a few refinements to the protocol were neces-
sary, but these occurred as recommended before any data
collection occurred [65]. The main change was the exclu-
sion of laboratory-based studies, studies of less than 4
weeks duration and cross-over studies from the review.
The initial scoping exercise had not revealed the large
numbers of such studies and attempting an analysis of all
these would have exceeded available resources.
Comparison with the existing literature
To our knowledge, this is the first large systematic re-
view of SAEs in people taking naltrexone, excluding
only those people taking opioids. Two large previous
systematic reviews of naltrexone in AUDs were con-
ducted by Rösner et al. [66] for the Cochrane Collabor-
ation and Jonas et al. [63] for the Agency for
Healthcare Research and Quality. Both examined AEs,
but in fewer studies. Rösner et al. [66] analysed nine
studies including two using injectable naltrexone, and
calculated the RD of experiencing SAEs as −0.02 (95%
CI −0.05–0.00). By using a wider range of studies and
inclusion criteria and limiting the publication dates
after the 1st of January 2001, this review was able to
provide a more accurate assessment of the risk of SAEs
than any previous review.
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Implications for researchers, clinicians and policy makers
The results of this review are supportive of the wider use
of naltrexone and have the realistic potential to impact on
clinical guidelines. Policy makers (e.g. US Preventative
Task Force and the National Institute of Clinical Excel-
lence) are encouraged to use the findings of this review in
conjunction with other studies focussed on benefits and
cost-effectiveness of naltrexone to draw/revise evidence-
based recommendations regarding the licensed use of nal-
trexone in a broader range of conditions. Treatment of
AUDs, for which naltrexone is currently under-utilised, is
a key area of consideration. Estimates suggest that about
58% of alcohol-dependent people in England want to re-
duce their drinking [67]. The increased use of pharmaco-
therapy for AUDs has been shown to be cost-effective and
could reduce deaths [68–70].
This review shows the advantages of examining both
benefit and risk profiles for drugs and the need for con-
sistent and adequate recording of AEs and SAEs in re-
ports of RCTs. Recent studies included in this review
still did not consistently report harms to the standard
suggested in the CONSORT extension for harms [33,
71], and differences in judgements on what constituted
an SAE were evident between studies. Research on the
efficacy of naltrexone for most diseases apart from
AUDs and opioid abuse is currently lacking; naltrexone
would seem an excellent candidate for repurposing
given it is both safe and cheap, being long out of patent.
It is also possible that naltrexone could be associated
with changes in the rates of cancers and cardiovascular
or cerebrovascular events given the complex interac-
tions of opioids in the body [72, 73]. Thus, both
large-scale pragmatic clinical trials of potentially new
indications for naltrexone, and systematic evaluations
through pharmaco-epidemiological studies using long-
term safety data (e.g. the UK Clinical Practice Research
Datalink (https://www.cprd.com/home/) are needed.
Conclusions
This systematic review and meta-analysis found no evi-
dence of a difference in risk of SAEs for oral naltrexone
compared to placebo. This evidence supports the use of
naltrexone in its currently licensed form and provides
solid support to contemporary efforts studying naltrex-
one where it is currently unlicensed.
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